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Introduction {#sec006}
============

There are about 71 million people with chronic hepatitis C virus infection world-wide \[[@pone.0193251.ref001]--[@pone.0193251.ref002]\]. Global control of hepatitis C virus (HCV) infection nowadays is an important healthy issue. As disease progresses, chronic hepatitis C (CHC) can result in the development of liver cirrhosis, hepatocellular carcinoma, and complications of liver diseases \[[@pone.0193251.ref003]--[@pone.0193251.ref005]\]. CHC also associates with extrahepatic disorders such as cardiovascular events or chronic kidney diseases \[[@pone.0193251.ref006]\]. Lines of evidence show that successful treatment to clear HCV exerts long-term beneficial effects on either hepatic or extrahepatic outcomes \[[@pone.0193251.ref007],[@pone.0193251.ref008]\].

With the advent of direct acting antiviral agents (DAA) in recent years, this new treatment provides patients and physicians an easier, shorter, safer, and highly efficient modality to clear HCV \[[@pone.0193251.ref009],[@pone.0193251.ref010]\]. For achieving the goal of HCV elimination set by World Health Organization (reducing new infections by 90% and mortality by 65%) by 2030 \[[@pone.0193251.ref011]\], efforts to enhance capacity or coverage of screening, to prevent new infection and reduce transmission, and to link infected subjects to medical care and curative treatment needs to be aggressively implemented. Among these issues or efforts, the base of HCV elimination is to expand the coverage of screening and to discover subjects who have HCV infection but not be tested or aware. However, little is known about the features of those subjects who are not aware of HCV infection. Understanding the characteristics of unaware HCV infected subjects and the difference from already known HCV infected subjects is important and may provide highlights to design further massive screening intervention.

In this study, we aimed to analyze the baseline demography of HCV infected residents in community who were already known infection or newly diagnosed infection by screening intervention. Through comparisons between these two kinds of infected residents, features of unaware HCV infected subjects are likely to be explored and recognized. In addition, we also evaluated the insights of liver diseases in already known HCV infected subjects in community to investigate the altitude and knowledge facing HCV infection.

Materials and methods {#sec007}
=====================

1. Screening intervention {#sec008}
-------------------------

We conducted screening activities of liver diseases in four remote villages (Jian-Jun, Chi-Koo, Hsin-Hwa, and Shen-Hwa) of Tainan City of southern Taiwan from August 2014 to July 2106. The study was approved by the Institutional Review Board of National Cheng Kung University Hospital. All residents participated in screening activities voluntarily and signed informed written consent. The process of screening intervention was described previously \[[@pone.0193251.ref012]\]. All patients were fasted for overnight before commencing screening intervention. Briefly, the intervention composed of two parts. The first part included recording baseline characteristics of participants, questionnaire (supporting information), waist/hip circumference measurement, blood sampling for viral markers and liver biochemical tests, abdominal sonography, and liver stiffness measurement by transient elastography (Echosens, France). The reliable measurement of liver stiffness measurement was defined as those valid measurements with less than 30% of Inter-quartile range/median. In questionnaire, current co-morbid diseases, knowledge of chronic liver diseases, detail history of alcohol and viral hepatitis, insights of liver diseases including current or history treatment or follow-up of viral hepatitis, history of occurrence of complications of liver diseases, and family history of liver diseases were asked and recorded by trained nurses. The trained nurses were unaware of HCV infection history of any participated residents. For the awareness of HCV infection, history of HCV examination was clarified and then classified as known HCV infection or unaware HCV infection according to the responded answer. Fatty liver on sonography was defined as the presence of liver-renal echo contrast and bright liver \[[@pone.0193251.ref013]\]. Those residents who showed fatty liver on sonography were considered to have non-alcoholic fatty liver disease (NAFLD).

The second part held two weeks later after first part. In this time period between first and second part, quantitation of HCV RNA was performed for all residents with positive anti-hepatitis C Antibody (anti-HCV). In the second part, we explained all of the examination reports to participants and referred those who required further evaluation or treatment to our hospital.

2. Laboratory tests {#sec009}
-------------------

Aspartate aminotransferase (AST, upper limit of normal is 38 U/L), alanine aminotransferase (ALT, upper limit of normal is 40 U/L), hepatitis B surface antigen (HBsAg; Architect HBsAg QT assay, Abbott, Chicago, IL), Anti-HCV (ARCHITECT Anti-HCV, ABBOTT, Diagnostics Division, Germany) were tested. Quantitation of HCV RNA (Abbott RealTime HCV quantitative assay; Abbott Molecular Inc., Des Plaines, IL, USA) was further determined in residents with positive anti-HCV.

3. Statistical analysis {#sec010}
-----------------------

Data were expressed as mean plus standard deviation. Groups were compared for distributed data by Student's t-test and for category data by Chi-square test or Fisher's exact test. Multivariate logistic regression analysis was performed to find factors associated with HCV infection or unaware HCV infection. P values less than 0.05 were considered to be significant. Finally, data handling and analysis were performed with SPSS software for Windows, version 17.0 (SPSS Inc., Chicago, IL).

Results {#sec011}
=======

1. Baseline characteristics {#sec012}
---------------------------

Of the 40000 estimated subjects in the screening couties, 1439 residents (3.6%) participated in the intervention voluntarily in the screening period. After exclusion of those residents with positive HBsAg (n = 131) and dual positivity of HBsAg and anti-HCV Ab (n = 23), non-HCV infection (both negative for HBsAg and anti-HCV and mono-HCV infection (positive anti-HCV) were observed in 1077 and 194 residents, respectively. Non-HCV infected residents exhibited the features of younger age, lower BMI, less WC and HC, higher ALT and AST levels, less hypertension and DM, higher values of controlled attenuation parameter (CAP), and lower values of liver stiffness than HCV infected residents "[Table 1](#pone.0193251.t001){ref-type="table"}". By multivariate logistic regression analysis, HCV infected residents had significant older age (p\<0.001), higher ALT levels (p\<0.001), higher liver stiffness (p = 0.010), and lower CAP values (p\<0.001).

10.1371/journal.pone.0193251.t001

###### Comparisons of demography of residents with status of HCV infection.

![](pone.0193251.t001){#pone.0193251.t001g}

                                             Univariate     Multivariate                                    
  ------------------------------------------ -------------- -------------- --------- ------- -------------- ---------
  Age (yrs)                                  54.8 ± 16.2    65.3 ± 11.8    \<0.001   1.052   1.037\~1.068   \<0.001
  ≤ 40                                       236            5              \<0.001                          
  40 \~ 50                                   152            13                                              
  50 \~ 60                                   252            41                                              
  60 \~ 70                                   236            69                                              
  \>70                                       20             66                                              
  Gender (M/F)                               440/637        77/117         0.241                            
  BMI (kg/m^2^)                              27.0 ± 13.0    24.6 ± 5.0     0.008     1.000   0.996\~1.004   0.998
  Waist circumference (cm)                   82.0 ± 12.1    86.1 ± 10.1    \<0.001   1.019   0.996\~1.042   0.112
  Hip circumference (cm)                     95.7 ± 9.7     97.2 ± 8.5     0.038     1.009   0.996\~1.037   0.528
  GOT (U/L)                                  27.0 ± 13.0    44.0 ± 57.3    \<0.001   0.011   0.995\~1.028   0.163
  GPT (U/L)                                  24.0 ± 17.3    45.0 ± 85.8    0.002     1.025   1.012\~1.038   \<0.001
  Liver stiffness (kPa)                      5.1 ± 5.2      7.7 ± 6.8      \<0.001   1.037   1.009\~1.067   0.010
  CAP (dB/m)                                 240.1 ± 54.4   227.8 ± 49.0   \<0.001   0.988   0.984\~0.992   \<0.001
  NAFLD (yes/no)                             545/532        89/105         0.313                            
  Smoking (yes/no)                           99/967         26/168         0.271                            
  Moderate alcohol consumption (yes/no)      68/998         16/178         0.435                            
  Hypertension (yes/no)                      257/809        75/119         \<0.001   1.287   0.856\~1.936   0.225
  Diabetes mellitus (yes/no)                 118/947        32/162         0.007     0.834   0.494\~1.406   0.495
  Dyslipidemia (yes/no)                      119/945        23/171         0.918                            
  Hyperuricemia (yes/no)                     40/1026        11/183         0.390                            
  Stroke history (yes/no)                    7/1059         5/189          0.057                            
  Heart diseases (yes/no)                    77/988         20/174         0.38                             
  Kidney diseases (yes/no)                   14/1052        5/189          0.172                            
  Thyroid diseases (yes/no)                  35/1031        5/189          1.000                            
  Family History of liver disease (yes/no)   219/845        48/146         0.392                            

Missing data in non-HCV subjects was observed.

The overall prevalence of HCV infection was 13.5%. They were tended to be in older age with 135 (69.6%) more than 60 years and female predominant. [Table 2](#pone.0193251.t002){ref-type="table"} shows the baseline characteristics of the 194 HCV infected participants. Diabetes mellitus, dyslipidemia, and hypertension were observed in 16.5%, 11.9%, and 38.7% of residents, respectively.

10.1371/journal.pone.0193251.t002

###### Characteristics of positive anti-HCV Ab subjects with known or unaware HCV infection.

![](pone.0193251.t002){#pone.0193251.t002g}

                                                            Univariate                    Multivariate                                 
  ------------------------------------------ -------------- -------------- -------------- -------------- ----- ------- --------------- -------
  Age (yrs)                                  65.3 ± 11.8    63.1 ± 10.8    69.2 ± 12.6    0.001          194   1.028   0.996\~1.0604   0.089
  ≤ 40                                       5              3              2              \<0.001                                      
  40 \~ 50                                   13             11             2                                                           
  50 \~ 60                                   41             31             10                                                          
  60 \~ 70                                   69             52             17                                                          
  \>70                                       66             29             37                                                          
  Gender (M/F)                               77/177         51/75          26/42          0.761                                        
  BMI (kg/m^2^)                              24.6 ± 5.0     25.6 ± 4.1     24.0 ± 3.8     0.008          194   0.933   0.851\~1.023    0.142
  Waist circumference (cm)                   86.1 ± 10.1    87.2 ± 10.7    84.0 ± 8.6     0.024          194   0.987   0.938\~1.037    0.597
  Abnormal WC (yes/no)                       101/93         71/55          30/38          0.136                                        
  Hip circumference (cm)                     97.2 ± 8.5     98.4 ± 8.4     95.2 ± 8.6     0.014          194   1.014   0.964\~1.066    0.594
  WHR                                        0.89 ± 0.08    0.89 ± 0.08    0.89 ± 0.08    0.886                                        
  Abnormal WHR                               76/118         47/80          29/38          0.400                                        
  GOT (U/L)                                  44.0 ± 57.3    43.5 ± 56.0    45.3 ± 60.7    0.831                                        
  GPT (U/L)                                  45.0 ± 85.8    40.7 ± 34.4    53.6 ± 138.1   0.452                                        
  Liver stiffness (kPa)                      7.7 ± 6.8      8.6 ± 8.3      6.1 ± 2.4      0.002          191   0.876   0.782\~0.981    0.022
  CAP (dB/m)                                 227.8 ± 49.0   229.4 ± 48.4   214.3 ± 48.4   0.043          190   0.998   0.990\~1.005    0.531
  NAFLD (yes/no)                             89/105         66/60          23/45          0.013          194   0.789   0.364\~1.710    0.548
  Smoking (yes/no)                           26/168         19/107         7/61           0.351                                        
  Moderate alcohol consumption (yes/no)      16/178         11/115         5/63           0.739                                        
  Hypertension (yes/no)                      75/119         49/77          26/42          0.929                                        
  Diabetes mellitus (yes/no)                 32/162         20/106         12/56          0.751                                        
  Dyslipidemia (yes/no)                      23/171         15/111         8/60           0.977                                        
  Hyperuricemia (yes/no)                     11/183         9/117          2/66           0.334                                        
  Stroke history (yes/no)                    5/189          4/122          1/67           0.659                                        
  Heart diseases (yes/no)                    20/174         6/120          15/54          0.001          194   6.082   1.963\~18.839   0.002
  Kidney diseases (yes/no)                   5/189          3/123          2/66           1.000                                        
  Thyroid diseases (yes/no)                  5/189          3/123          2/66           1.000                                        
  Family History of liver disease (yes/no)   48/146         40/86          8/68           0.002          194   0.291   0.113\~0.750    0.011

2. Comparisons between residents with already known or previously unaware HCV infection {#sec013}
---------------------------------------------------------------------------------------

Among the 194 residents with HCV infection, 68 (35.1%) did not have the awareness of HCV infection before and 119 (61.3%) exhibited HCV viremia. We analyzed the difference of characteristics between already known HCV infected subjects and previously unaware HCV infected subjects. Residents with previously unaware HCV infection exhibited significant older age (p = 0.001), lower BMI (p = 0.008), less waist and hip circumferences (p = 0.024 and p = 0.014), lower values of liver stiffness (p = 0.002) and controlled attenuation parameter (CAP; p = 0.043), less prevalence of NAFLD (p = 0.013) and heart diseases (p = 0.002), and less cluster of family history of liver diseases (p = 0.002) "[Table 2](#pone.0193251.t002){ref-type="table"}". Comparison was also performed in the 119 viremic residents, including 76 (62.2%) already known HCV infection and 45 (37.8%) previously unaware HCV infection. Similar factors were observed and showed in [Table 3](#pone.0193251.t003){ref-type="table"}.

10.1371/journal.pone.0193251.t003

###### The characteristics of HCV viremic patients with already known or unaware HCV infection.
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                                                            Univariate                    Multivariate                                
  ------------------------------------------ -------------- -------------- -------------- -------------- ----- ------- -------------- -------
  Age (years)                                66.3 ± 12.4    64.1 ± 14.3    69.7 ± 13.5    0.025          119   0.987   0.952\~1.024   0.485
  ≤ 40                                       2              1              1              0.134                                       
  40 \~ 50                                   9              7              2                                                          
  50 \~ 60                                   22             14             8                                                          
  60 \~ 70                                   39             29             10                                                         
  \>70                                       47             23             24                                                         
  Gender (M/F)                               72/47          28/46          19/26          0.635                                       
  BMI (kg/m^2^)                              24.7 ± 4.7     25.5 ± 4.3     24.0 ± 3.7     0.045          119   1.059   0.951\~1.180   0.296
  Waist circumference (cm)                   85.7 ± 10.5    86.4 ± 11.4    84.4 ± 9.0     0.292                                       
  Abnormal WC                                56/63          32/42          24/21          0.261                                       
  Hip circumference (cm)                     97.1 ± 9.0     98.0 ± 9.2     95.8 ± 8.6     0.203                                       
  WHR                                        0.88 ± 0.08    0.88 ± 0.09    0.88 ± 0.07    0.994                                       
  Abnormal WHR                               48/71          30/44          18/27          0.984                                       
  GOT (U/L)                                  50.0 ±67.3     51.5 ± 70.3    47.9 ± 63.6    0.778                                       
  GPT (U/L)                                  55.1 ± 104.6   50.7 ± 40.9    63.1 ± 163.4   0.533                                       
  Liver stiffness (kPa)                      8.2 ± 7.5      9.3 ± 9.2      6.2 ± 2.0      0.006          117   1.187   1.029\~1.369   0.019
  CAP (dB/m)                                 219.9 ± 49.8   226.7 ± 50.1   207.5 ± 47.6   0.045          117   1.004   0.995\~1.014   0.352
  NAFLD (yes/no)                             51/68          37/37          14/31          0.043                                       
  Smoking (yes/no)                           18/101         13/61          5/40           0.340                                       
  Moderate alcohol consumption (yes/no)      11/108         7/67           4/41           0.917                                       
  Hypertension (yes/no)                      43/78          28/46          15/30          0.620                                       
  Diabetes Mellitus (yes/no)                 22/97          14/60          8/37           0.876                                       
  Dyslipidemia (yes/no)                      8/111          5/69           3/42           1.000                                       
  Hyperuricemia (yes/no)                     6/113          6/68           0/45           0.082                                       
  Stroke history (yes/no)                    4/115          3/71           1/44           1.000                                       
  Heart diseases (yes/no)                    12/107         3/71           9/36           0.009          119   0.112   0.021\~0.603   0.011
  Kidney diseases (yes/no)                   3/116          1/73           2/49           0.556                                       
  Thyroid diseases (yes/no)                  3/116          2/72           1/44           1.000                                       
  Family History of liver disease (yes/no)   31/88          24/50          7/38           0.042          119   2.390   0.787\~7.263   0.124

We further performed multivariate logistic regression analysis to find factors associated with the unaware HCV infection. Less fibrosis severity (OR 0.876, 95% CI 0.782\~0.981, p = 0.022), more prevalent of heart diseases (OR 6.082, 95% CI 1.963\~18.839, p = 0.002), and less cluster of family history of liver diseases (OR 0.291, 95% CI 0.113\~0.750, p = 0.011) were the independent factors "[Table 2](#pone.0193251.t002){ref-type="table"}". For HCV viremic residents, unaware HCV infected residents were associated with less fibrosis severity (OR 1.187, 95% CI 1.029\~1.369, p = 0.019) and more prevalent of heart diseases (OR 0.112, 95% CI 0.021\~0.603, p = 0.011) "[Table 3](#pone.0193251.t003){ref-type="table"}".

3. Insights of liver diseases in HCV infected residents {#sec014}
-------------------------------------------------------

For understanding the altitude or knowledge of facing HCV infection, we evaluated the insights of liver diseases in 126 already known HCV infected residents. Only 59 (46.8%) of them had current or history of antiviral treatment or regular follow-up at hospital. Six patients received pegylated interferon/ribavirin treatment and achieved sustained virological response. In remaining residents, 30 (23.8%) did not have any concept of treatment or follow-up; 14 (11.1%) did not have any willing to treatment or follow-up due to no symptoms; 10 (7.9%) was informed not requiring to receive treatment or follow-up by general physicians. [Fig 1](#pone.0193251.g001){ref-type="fig"} shows the detail distribution of disease insights.

![The distribution of disease insights in 126 already known HCV infected residents.](pone.0193251.g001){#pone.0193251.g001}

Discussion {#sec015}
==========

This screening intervention is a community-based approach to discover or screen residents in HCV and HBV endemic villages in southern Taiwan. In this study, higher prevalence of HCV infection (13.5%) than that of general population in Taiwan indicated that these villages were HCV endemic area \[[@pone.0193251.ref014],[@pone.0193251.ref015]\]. Not surprisingly, HCV infected residents were older and more significant liver injury than non-HCV infected residents. Of the HCV infected residents, about one third of them were unaware of infection before participating in screening intervention. They exhibited different features from those already known HCV infected residents in older age, less BMI, milder liver fibrosis and less prevalence of NAFLD, and less family cluster of liver diseases. The target population of this study is quite different from previous reports \[[@pone.0193251.ref016],[@pone.0193251.ref017]\]. Residents lived in known HCV endemic and remote villages of Taiwan would be a distinct and special population. Relatively poor healthy knowledge and resources, long transportation distance to hospital, predominantly older people, and lower socioeconomic status are the main characteristics of residents in remote villages of southern Taiwan. In addition, there was a lack of report that described the comparison between already known and unaware HCV infected residents in community.

The unaware HCV infected subjects is a distinct and important population nowadays. We found that 35% of residents were unaware of HCV infection before participating in screening intervention which was higher than previous reports from Taiwan (about 15%) \[[@pone.0193251.ref018],[@pone.0193251.ref019]\]. The difference mainly based on the screening sites as our screening intervention focused on remote villages whereas other screening intervention focused on urban and rural regions \[[@pone.0193251.ref018],[@pone.0193251.ref019]\]. The proportion and population of unaware of HCV infection is also different from a report from Western country \[[@pone.0193251.ref020]\]. This result indicated that a substantial group of HCV infected residents remained undiscovered even after rigorous screening activities conducted by local government or non-governmental organizations (NGOs) for many years in remote villages of Taiwan. There are many reasons that the previously unaware infected residents could be discovered in this study. In our screening intervention, we contacted local representatives of villages to join and to play an active role in encouraging residents to participate in activities, including broadcasting screening activity news and spreading leaflets in villages. In addition, the remote villages often exhibit relatively poor health resources and long distance to reach hospital. Screening activities held locally that may enhance the incentives of residents to participate in. This screening model is different from those reported before and may be considered as a valuable option for HCV endemic regions.

Understanding the characteristics of previously unaware infected residents or subjects is an important issue that seldom addressed before. In this study, residents with previously unaware HCV infection exhibited features of mild severity of liver diseases, higher rates of heart diseases, and less family cluster of liver diseases. The mild disease severity by measuring the liver stiffness implicated that this kind of infected subjects probably were less symptomatic and then consequently resulted in less opportunities to seek for medical aids. Disease severity may also associate with genetic background. Lines of evidence showed that *IL28B* and *PNPLA3* polymorphism were associated with advanced liver diseases and steatosis in chronic hepatitis C \[[@pone.0193251.ref021]--[@pone.0193251.ref023]\]. Although genetic factors such as PNPAL3 or others did not survey in this study, genetic predisposing cannot be totally excluded.

Residents with family history of liver diseases theoretically gain more health knowledge and have more incentive to test whether they got hepatitis virus infection. Infected family members may also urge other members to evaluate the hepatitis virus infection. Hence, family with current or history of liver diseases may cause a positive feedback circus within family. Unaware of HCV infected residents seem to be lack of these external effects that probably make them persistently undiscovered.

Unaware HCV infection residents presented with more prevalence of heart diseases. The only observed risk factor in this study was older age. There was no difference in the prevalence of diabetes mellitus, hypertension, smoking history, and alcohol consumption. However, already known HCV infected residents had risk factors such as higher waist/hip circumferences and more NAFLD that both could associate with the occurrence of heart diseases \[[@pone.0193251.ref024],[@pone.0193251.ref025]\]. At present, we could not explain this association well.

In this study, less than half of infected residents have been treated or followed at hospital in community of southern Taiwan. One third of residents had insights of no concept or no willing to treat or follow-up. All these three factors indicated that both heath knowledge and linkage to medical care of HCV infected residents were poor in remote villages. Barriers that may associate with these features include long transportation distance to referral or medical centers, poor health resources of villages to evaluate disease severity, lack of call-back or follow-up system, and insufficient manpower including healthy workers and public officers to educate or actively refer these infected residents. The best strategies to HCV elimination should put more efforts to minimize the gap between screening and active treatment \[[@pone.0193251.ref026]\], especially in high effectiveness DAA era. The actions shall include broadening screening coverage in known HCV endemic villages, cooperating with local government or NGOs to maximize screening resources and to actively refer for medical care, and educating general physicians and residents of update knowledge of liver diseases and treatments.

There are limitations of this study. Although this is a prospective study, we did not store enough blood samples to perform genetic or additional biochemical tests. The findings of this study were based on the population of HCV endemic remote villages in Taiwan and may not be applied to general population.

Conclusions {#sec016}
===========

In conclusion, unaware of HCV infected residents represented a substantial and distinct HCV infected population with obscure characteristics in community. To augment the linkage of medical care to known HCV infected residents and discover unaware infected residents, further work including how to enhance screening coverage, methods to identify liver disease severity, efforts to propagate adequate or update knowledge of liver diseases, and establish efficient call-back or follow-up system should be addressed.
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